Alpha-1 antitrypsin deficiency is a common single-gene disorder, in which the most common mutant """"""""Z"""""""" allele (Glu342Lys) occurs with remarkably high frequency in Northern Europeans and North Americans. Homozygous Z patients suffer from a lung disease that is due to the lack of normal antiprotease function of the wild-type AAT, and may also suffer from a liver disease, that appears to be triggered by retention of polymeric and/or aggregated Z-AAT protein within hepatocytes. A mouse model expressing the human Z-allele has utility in examining molecular endpoints but does not faithfully reproduce the inflammation and cirrhosis observed in severely affected patients. In this application, we propose to develop better models of AAT-related liver disease using environmental challenges and human stem cell derived liver chimeras, and further to test a combined gene therapy/RNA inhibition strategy as a potential future therapy.
Our first aim will use an ethanol induce hepatotoxicity in mice with the human Z allele to assess the risk of increased risk hepatocellualr carcinoma and to better understand the pro-inflammatory and pro-fibrotic pathways in these livers. This concept will then be extended to studies using humanized mouse livers with either normal or Z-allele positive human liver stem cells derived from iPS cells. Finally both of these models will be utilized to assess the effect of rAAV-based RNAi mediated knockdown of the Z-AAT mRNA.

Public Health Relevance

Alpha-1 antitrypsin deficiency is a common single-gene disorder, in which the most common mutant Z allele (Glu342Lys) occurs with remarkably high frequency in Northern Europeans and North Americans. Homozygous Z patients suffer from a lung disease that is due to the lack of normal antiprotease function of the wild-type AAT, and may also suffer from a liver disease, that appears to be triggered by retention of polymeric and/or aggregated Z-AAT protein within hepatocytes. A mouse model expressing the human Z-allele has utility in examining molecular endpoints but does not faithfully reproduce the inflammation and cirrhosis observed in severely affected patients. In this application, we propose to develop better models of AAT-related liver disease using environmental challenges and human stem cell derived liver chimeras, and further to test a combined gene therapy/RNA inhibition strategy as a potential future therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK098252-01
Application #
8478265
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Doo, Edward
Project Start
2013-05-27
Project End
2017-04-30
Budget Start
2013-05-27
Budget End
2014-04-30
Support Year
1
Fiscal Year
2013
Total Cost
$361,956
Indirect Cost
$144,456
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Borel, Florie; Sun, Huaming; Zieger, Marina et al. (2018) Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. Proc Natl Acad Sci U S A 115:2788-2793
Mueller, Christian; Gernoux, Gwladys; Gruntman, Alisha M et al. (2017) 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. Mol Ther 25:1387-1394
Gernoux, Gwladys; Wilson, James M; Mueller, Christian (2017) Regulatory and Exhausted T Cell Responses to AAV Capsid. Hum Gene Ther 28:338-349
Borel, Florie; Tang, Qiushi; Gernoux, Gwladys et al. (2017) Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of ?-1 Antitrypsin Deficiency. Mol Ther 25:2477-2489
Loring, Heather S; ElMallah, Mai K; Flotte, Terence R (2016) Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans. Hum Gene Ther Methods 27:49-58
Gruntman, Alisha M; Su, Lin; Su, Qin et al. (2015) Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials. Hum Gene Ther Methods 26:71-6
Borel, Florie; Kay, Mark A; Mueller, Christian (2014) Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 22:692-701
Flotte, Terence R; Mueller, Christian (2014) What is suppression of anti-adeno-associated virus capsid T-cells achieving? Hum Gene Ther 25:178-9
Kiem, Hans-Peter; Baum, Christopher; Bushman, Frederic D et al. (2014) Charting a clear path: the ASGCT Standardized Pathways Conference. Mol Ther 22:1235-1238